On Wednesday, shares in Gaithersburg, Maryland headquartered Novavax Inc. recorded a trading volume of 6.47 million shares. The stock ended the day at $1.31, rising 3.15% from the last trading session. The Company's shares have advanced 5.65% in the last one month and 3.97% since the start of this year. The stock is trading below its 50-day moving average by 4.56%. Furthermore, shares of Novavax, which focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants, have a Relative Strength Index (RSI) of 49.55.
On November 09th, 2016, Novavax reported a net loss of $66.3 million, or $0.24 per share, for Q3 2016, compared to a net loss of $33.1 million, or $0.12 per share, for Q3 2015. Novavax revenue in Q3 2016 decreased 50% to $3.2 million compared to $6.5 million for Q3 2015. Lower revenue under the HHS BARDA contract of $6.2 million is the primary driver of this decrease. Sign up and read the free research report on NVAX at:
Foster City, California headquartered Gilead Sciences Inc.'s stock climbed 2.99%, finishing yesterday's session at $76.38. A total volume of 14.83 million shares was traded, which was above their three months average volume of 9.48 million shares. The Company's shares have gained 6.15% in the last month and 6.66% on an YTD basis. The stock is trading above its 50-day moving average by 3.40%. Additionally, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia/Pacific, have an RSI of 63.40.
On January 03rd, 2017, Gilead Sciences announced that Alessandro Riva, MD, will join the Company as Senior Vice President of Hematology and Oncology Therapeutic Area Head. In this position, Dr. Riva will report to John McHutchison, MD, Executive Vice President of Clinical Research and will have responsibility for Gilead's hematology and oncology programs. Alessandro will also join Gilead's Executive Committee. The complimentary research report on GILD can be downloaded at:
Shares in Cambridge, Massachusetts headquartered ARIAD Pharmaceuticals Inc. ended Wednesday's session 5.58% higher at $13.06. The stock recorded a trading volume of 6.99 million shares, which was above its three months average volume of 6.57 million shares. The Company's shares have gained 4.98% on an YTD basis. The stock is trading 9.76% above its 50-day moving average and 34.31% above its 200-day moving average. Moreover, shares of ARIAD Pharma, which engages in the discovery, development, and commercialization of drugs for cancer patients in the US and internationally, have an RSI of 63.04.
On December 07th, 2016, ARIAD Pharmaceuticals announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in ALK-positive non-small cell lung cancer patients who had experienced disease progression on crizotinib therapy. The company stated that as of May 31st, 2016, the data show that of patients on the 180-mg regimen with a median follow-up of 11 months, 55% achieved confirmed objective response as assessed by the investigator. In this arm, the median progression-free survival was 15.6 months in this post-crizotinib setting, by both investigator and independent review committee assessment. Register for free on Stock-Callers.com and access the latest report on ARIA at:
At the close, South San Francisco, California headquartered Exelixis Inc.'s stock edged 3.87% higher, finishing at $15.30. A total volume of 4.60 million shares was traded. The Company's shares have gained 2.62% since the start of this year. The stock is trading 1.69% and 51.79% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 51.05.
On January 03rd, 2017, Exelixis announced that it granted restricted stock unit awards representing an aggregate of 17,750 shares of Exelixis' common stock, and stock options to purchase an aggregate of 35,500 shares of Exelixis' common stock to 11 new employees. The stock options have an exercise price of $14.91 per share, which is equal to the closing price of Exelixis' common stock on December 30th, 2016. Get free access to your research report on EXEL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA